| [1] |
徐蕊, 黄兴兵. 难治性抑郁症非药物治疗新进展[J]. 实用医学杂志, 2024, 40(4):439-446.
|
|
Xu R, Huang XB. Progress of non-pharmacological treatments for treatment-resistant depression[J]. J Pract Med, 2024, 40(4):439-446.
|
| [2] |
李凌江, 马辛. 中国抑郁障碍防治指南[M]. 2版. 北京: 中华医学电子音像出版社, 2015.
|
|
Li LJ, Ma X. Guidelines for prevention and treatment of de-pressive disorder in China[M]. 2nd ed. Beijing: China Medical Multimedia Publishing House, 2015.
|
| [3] |
Bahr R, Lopez A, Rey JA. Intranasal esketamine(SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant[J]. P&T, 2019, 44(6):340-375.
|
| [4] |
Buchmayer F, Kasper S. Overcoming the myths of esketamine administration:different and not difficult[J]. Front Psychiatry, 2023, 14:1279657.
|
| [5] |
Doty RL, Popova V, Wylie C, et al. Effect of esketamine nasal spray on olfactory function and nasal tolerability in patients with treatment-resistant depression:results from four multi-center,randomized,double-blind,placebo-controlled,phase Ⅲ studies[J]. CNS Drugs, 2021, 35(7):781-794.
|
| [6] |
朱秀清, 温预关. 艾司氯胺酮鼻喷雾剂临床使用管理专家共识[J]. 今日药学, 2025:1-14.
|
|
Zhu XQ, Wen YG. Expert consensus on clinical use mana-gement of esketamine nasal spray[J]. Pharm Today, 2025:1-14.
|
| [7] |
Chepke C, Shelton R, Sanacora G, et al. Real-world safety of esketamine nasal spray:a comprehensive analysis of esketa-mine and respiratory depression[J]. Int J Neuropsychopharmacol, 2024, 27(12):pyae058.
|
| [8] |
Wang SM, Kim NY, Na HR, et al. Rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation:a meta-analysis[J]. Clin Psychopharmacol Neurosci, 2021, 19(2):341-354.
|
| [9] |
Doherty T, Wajs E, Melkote R, et al. Cardiac safety of esketa-mine nasal spray in treatment-resistant depression:results from the clinical development program[J]. CNS Drugs, 2020, 34(3):299-310.
|
| [10] |
Siegel AN, Di Vincenzo JD, Brietzke E, et al. Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality:a systematic review[J]. J Psychiatr Res, 2021, 137:426-436.
|
| [11] |
王晨, 许冬梅, 邵静, 等. 精神科住院抑郁症患者自杀预防及护理干预措施专家共识[J]. 中华护理杂志, 2022, 57(18):2181-2185.
|
|
Wang C, Xu DM, Shao J, et al. Expert consensus of suicide care interventions for psychiatric inpatients with depression[J]. Chin J Nurs, 2022, 57(18):2181-2185.
|
| [12] |
Pompili M, Sarli G, Erbuto D, et al. Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency:case presenta-tions[J]. Int Clin Psychopharmacol, 2023, 38(3):195-200.
|
| [13] |
Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale(CADSS)[J]. J Trauma Stress, 1998, 11(1):125-136.
DOI
PMID
|
| [14] |
Pereira S, Brennan E, Patel A, et al. Managing dissociative sy-mptoms following the use of esketamine nasal spray:a case report[J]. Int Clin Psychopharmacol, 2021, 36(1):54-57.
|
| [15] |
Yang S, Wang J, Li X, et al. Adverse effects of esketamine for the treatment of major depression disorder:findings from ran-domized controlled trials[J]. Psychiatr Q, 2022, 93(1):81-95.
|